$Sarepta Therap(SRPT.US) | 𝐒𝐚𝐫𝐞𝐩𝐭𝐚: H.C. Wainwright reiterates 𝐒𝐞𝐥𝐥, maintains 𝐏𝐓 𝐚𝐭 $𝟓
Analyst sees rising efficacy risks from new Roche study, with limited upside and significant downside to core U.S. ELEVIDYS franchise.Source: Hardik Shah
Roche
RHHBY----
Share your thoughts
Write something you'd like to share with our community...
- B
RXRX 一周展望，By Grok
$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...
